Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LDHA | P00338 | 1/20 | 0.48 |
| ▸ | LDHB | P07195 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26144915 | 0.96 | KMT2A (0.53) | ALDH1A1KMT2ALMNAPOLBEPHX2 | |
| SCHEMBL26144918 | 0.94 | KMT2A (0.55) | ALDH1A1KMT2ALMNAPOLBHTR2B | |
| SCHEMBL13543487 | 0.84 | CA1 (0.62) | KMT2AHTR2BCA1CA2CYP2C19 | |
| SCHEMBL24170905 | 0.81 | CTSL (0.45) | ALDH1A1KMT2ALMNAPOLBCCR8 | |
| SCHEMBL17479215 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KMT2ALMNAPOLBEPHX2 | |
| SCHEMBL925723 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KMT2ALMNAPOLBEPHX2 | |
| SCHEMBL24998954 | 0.79 | CA12 (0.48) | ALDH1A1KMT2ALMNAPOLBCA1 | |
| SCHEMBL24998955 | 0.79 | CA12 (0.48) | ALDH1A1KMT2ALMNAPOLBCA1 | |
| SCHEMBL22333502 | 0.79 | HTR2B (0.65) | ALDH1A1KMT2ALMNAPOLBHTR2B | |
| SCHEMBL17115711 | 0.79 | HTR2B (0.65) | ALDH1A1KMT2ALMNAPOLBHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4175949-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-05-10 | — | — | EP | claimed |
| CN-115989223-A | Methods and compositions for targeting Tregs using CCR8 inhibitors | 南京艾美斐生物医药科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| US-12552753-B2 | Methods and compositions for targeting Tregs using CCR8 inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| WO-2022000443-A1 | METHODS AND COMPOSITIONS FOR TARGETING TREGS USING CCR8 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | ALDH1A1 2716/4885KMT2A 2533/4885LMNA 4214/4885 |
| US-12552753-B2 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | ALDH1A1 4520/4885KMT2A 4548/4885LMNA 4530/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | ALDH1A1 2716/4885KMT2A 2533/4885LMNA 4214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.